Key Insights

Highlights

Success Rate

75% trial completion

Published Results

17 trials with published results (23%)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

16.2%

12 terminated out of 74 trials

Success Rate

75.0%

-11.6% vs benchmark

Late-Stage Pipeline

1%

1 trials in Phase 3/4

Results Transparency

47%

17 of 36 completed with results

Key Signals

17 with results75% success12 terminated

Data Visualizations

Phase Distribution

53Total
Not Applicable (12)
Early P 1 (1)
P 1 (22)
P 2 (17)
P 3 (1)

Trial Status

Completed36
Recruiting13
Terminated12
Unknown4
Withdrawn3
Active Not Recruiting3

Trial Success Rate

75.0%

Benchmark: 86.6%

Based on 36 completed trials

Clinical Trials (74)

Showing 20 of 20 trials
NCT07005297Not Yet Recruiting

Clinical Genetics Branch Eligibility Screening Survey

NCT06744283RecruitingPrimary

Experience and Management of Cancer Screening-Related Anxiety in Fanconi Anemia

NCT00027274Recruiting

Cancer in Inherited Bone Marrow Failure Syndromes

NCT05687149RecruitingPrimary

Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia

NCT05973656Not ApplicableRecruiting

Role of Acetaldehyde in the Development of Oral Cancer

NCT07649031RecruitingPrimary

MRI as Noninvasive Innovative Approach in Detection and Monitoring of Malignant Oral Lesions in Fanconi Anemia Patients

NCT03351868Not ApplicableRecruitingPrimary

FANCA Gene Transfer for Fanconi Anemia Using a High-safety, High-efficiency, Self-inactivating Lentiviral Vector

NCT03050268Recruiting

Familial Investigations of Childhood Cancer Predisposition

NCT07408583Phase 1Not Yet RecruitingPrimary

Prenatal Transplantation for Fetuses With Fanconi Anemia

NCT02720679Recruiting

Investigation of the Genetics of Hematologic Diseases

NCT06648096Phase 1RecruitingPrimary

Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT03476330Phase 2CompletedPrimary

Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia

NCT07527975Enrolling By InvitationPrimary

Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the Infusion of RP-L102

NCT04437771Active Not Recruiting

Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy

NCT00542373Not ApplicableActive Not Recruiting

Widefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for Developing Oral Cancer

NCT06731036Unknown

Expanded Access to CD34+ Selection Utilizing Miltenyi CliniMACS Prodigy® for Patients Receiving Peripheral Blood Stem Cell Transplantations and Stem Cell Boosts

NCT03579875Phase 2RecruitingPrimary

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

NCT04784052Phase 1RecruitingPrimary

Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab

NCT04232085Phase 2Recruiting

Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures

NCT02143830Phase 2RecruitingPrimary

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Scroll to load more

Research Network

Activity Timeline